Published on 22/12/2025
How Location Influences Clinical Trial Site Selection Decisions
Introduction: Why Geography Matters in Clinical Trials
Site location is a foundational pillar of clinical trial success. The geographic positioning of an investigator site influences patient accessibility, enrollment velocity, compliance with local regulations, infrastructure availability, and cost of operations. In today’s globalized research ecosystem, selecting the right site in the right place is not merely a logistical task—it is a strategic decision with direct implications on data quality, trial timelines, and regulatory acceptability.
This article explores the critical role of location in site selection, supported by real-world examples, data-driven criteria, and regulatory considerations that guide geographic feasibility in clinical development.
1. Geographic Access to Target Patient Populations
The primary reason sponsors evaluate location is proximity to the intended patient population. A well-located site should have access to a sufficient catchment area of eligible patients based on:
- Prevalence and incidence of the disease
- Socioeconomic profiles and willingness to participate
- Referral networks with primary or tertiary care centers
- Local diagnostic capacity (e.g., imaging, lab facilities)
Example: In a chronic kidney disease study, sites located within 15 km of major nephrology centers enrolled 30% faster compared to suburban clinics with poor specialist connectivity.
2. Infrastructure Readiness and
Not all geographic regions have equal access to research infrastructure. Before selecting a site, sponsors must assess:
- Availability of equipment (e.g., ECG, imaging, pharmacy storage)
- Access to GCP-trained staff and investigators
- Power, internet, and backup systems for EDC/eSource access
- Nearby emergency facilities
Urban centers often offer infrastructure advantages but may suffer from overcommitted staff or higher competition for patient recruitment.
3. Local Regulatory and Ethics Frameworks by Region
Location determines the regulatory and ethics committee landscape. Some regions have longer IRB/IEC timelines, additional documentation requirements, or specific import/export limitations for investigational products.
Comparative Example:
| Country | Avg. Ethics Approval Time | Import Licensing Needed? |
|---|---|---|
| Germany | 28–45 days | No |
| India | 45–75 days | Yes |
| Brazil | 60–90 days | Yes |
Incorporating such timelines into feasibility analysis ensures realistic startup projections and resource planning.
4. Location and Subject Retention Challenges
Geography can influence subject drop-out rates. Long travel distances, poor public transport, or seasonal weather extremes may reduce follow-up compliance.
Sample Data:
- Sites located >20 km from the patient population center saw 18% higher early discontinuation in an oncology study.
- Mountainous or flood-prone areas had delayed visit adherence during seasonal periods.
Such insights should be factored into risk-based monitoring and retention strategy plans.
5. Cost Considerations Based on Geography
Site location directly impacts operational costs:
- Site staff salaries and overheads vary by country and city
- Shipment and IP logistics increase in remote areas
- Monitoring travel costs scale with site remoteness
- Translation and back-translation requirements for local populations
Example: A sponsor evaluating sites in Canada found that rural sites added $2500/month in CRA travel costs versus city-based sites with same enrollment potential.
6. Role of Location in Regulatory Acceptance of Data
For global studies, location also affects regulatory perceptions. Agencies may scrutinize data from sites in high-risk geographies or unfamiliar oversight frameworks.
Example: The FDA has requested clarification on data integrity and monitoring when a majority of trial subjects were recruited from a single low-income region with limited historical submissions.
Balanced site distribution across regulatory regions improves submission robustness and acceptability.
7. Geographic Diversity for Representativeness
Ensuring geographic diversity is increasingly tied to broader diversity and inclusion goals. FDA and EMA recommend that trials include data from various regions and populations, especially in pivotal studies.
Geographic inclusion improves external validity of findings and aligns with patient access mandates in post-marketing commitments.
8. Site Density and Competition
Sites located in metropolitan research hubs may face intense competition for subjects due to multiple concurrent trials. Sponsors should assess:
- Overlapping trial enrollments
- Referral fragmentation
- Investigator burden across sponsors
Low-density regions may offer better recruitment opportunities, albeit with infrastructure trade-offs.
Conclusion
Location is more than a point on a map—it is a complex determinant of trial performance, regulatory acceptability, and operational feasibility. By evaluating geographic factors such as population access, infrastructure, costs, regulatory timelines, and retention dynamics, sponsors can make informed, risk-adjusted decisions in site selection. An integrated approach that combines EDC, CTMS, epidemiological, and geographic data is key to optimizing global clinical development strategies and ensuring trial success.